Procept Biorobotics Corp

Given the ongoing Stage 4 downtrend with price below key SMAs and lower highs persisting, the medium-term bias remains bearish. However, bearish exhaustion signals suggest near-term seller fatigue and potential short-term bounces. Under the speculative strategy, trimming into rallies around the 9/20/50 EMAs at prior support-turned-resistance areas is the preferred approach. A lack of decisive reversal above intermediate structure maintains bearish bias while deferring execution to favorable retracements.

• ↑Q1 revenue up 20.1% YoY; Q2 2026 guidance at $92.6M confirms growth
• ↑Robotic BPH system adoption rising, offering precision advantage over alternatives
• ↓Projected Q2 2026 loss of $0.46 per share highlights ongoing unprofitability